{"id":"nct:NCT07587021","kind":"trial","title":"Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)","authors":["YolTech Therapeutics Co., Ltd"],"author_count":1,"year":2026,"published":"2026-05-14","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07587021","source_url":"https://clinicaltrials.gov/study/NCT07587021","archive_url":"https://space-kitty.com/papers/nct:NCT07587021","updated":"2026-10-09","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This study will be conducted to evaluate the efficacy and safety of YOLT-203 in children and adults with Primary Hyperoxaluria Type 1. After the initial randomized, 6-month double-blind, placebo-controlled period, participants who were initially assigned to placebo will receive a single-dose of YOLT-203 treatment whereas participants in the YOLT-203 group will receive a single-dose of placebo infusion. For patients interested in additional information on how to participate, please follow this link: https://mytomorro.ws/ph1trial.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Primary Hyperoxaluria Type 1","PH1"],"details":{"acronym":null,"status":"RECRUITING","phase":"PHASE2","study_type":"INTERVENTIONAL","enrollment":36,"sponsor":"YolTech Therapeutics Co., Ltd","conditions":["Primary Hyperoxaluria Type 1","PH1"],"interventions":["GENETIC: YOLT-203","DRUG: Placebo"],"start_date":"2026-09-16","start_date_type":"ACTUAL","primary_completion_date":"2027-08-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"gene-editing-therapies","name":"CRISPR & Gene-Editing Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[]}